{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-23-000014","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.127190+00:00","generated_at":"2026-06-18T17:08:34.811229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jazz Pharma reports record 2022 revenue of $3.7B, up 18% YoY; guides 2023 revenue $3.675-3.875B","bullets":["Record 2022 total revenue $3.7B (+18% YoY); 2023 revenue guidance $3.675-3.875B (3% growth at midpoint).","Xywav became largest product in Q4, annualizing >$1B; more narcolepsy patients on Xywav than Xyrem.","Cash from operations $1.3B in 2022; delevered balance sheet to 2.9x adjusted net leverage.","Pipeline progress: positive zanidatamab pivotal trial in BTC; Phase 2 suvecaltamide in Parkinson's tremor enrolled.","FDA approved Rylaze sBLA for MWF IM dosing; Epidyolex launched in all five key EU markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-23-000014","json":"https://secwatch.observer/filing/0001232524-23-000014.json","markdown":"https://secwatch.observer/filing/0001232524-23-000014.md","text":"https://secwatch.observer/filing/0001232524-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/jazz-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:08:34.811229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a264c50208149f8abea91b1975549c2d797c3c50","claim":"Jazz Pharmaceuticals plc reported full year 2023 results: revenue $3,675 to $3,875 million. Guidance initiated.","evidence_excerpt":"2023 total revenue guidance of $3,675 to $3,875 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$3,675 to $3,875 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c0cf78e259118715fb999aeb144f77a36117c528","claim":"Jazz Pharmaceuticals plc reported full year and fourth quarter ended December 31, 2022 results: revenue $3.7 billion.","evidence_excerpt":"Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000123252423000014/0001232524-23-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year and fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$3.7 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}